LeungEHAlsoudiAFSkrehotHC, et al. Risk for ocular hypertension with intravitreal dexamethasone implants in Black and White patients with diabetic macular edema. J Vitreoretin Dis. 2025;9(3):291–296.
2.
PatelHAllenAKarlJ, et al. Diabetic retinopathy disease burden in patients with lower household incomes vs higher household incomes. J Vitreoretin Dis. 2025;9(3):297–302.
3.
NiYXingSChenBZhangZ.Yin-Yang staining technique to create a nonstained internal limiting membrane flap to cover large idiopathic macular holes. J Vitreoretin Dis. 2025;9(3):303–307.
4.
KavoussiSC.Infrared video imaging for the identification and quantification of macula-involving symptomatic vitreous opacities. J Vitreoretin Dis. 2025;9(3):308–312.
5.
GunawardeneANSuraneniSRohowetzLJSridharJ.Characteristics and medical accuracy of online discussions of retinal conditions on a social media platform. J Vitreoretin Dis. 2025;9(3):313–317.
6.
WilkinsCSEsquenaziKHirabayashiK, et al. Vitreoretinal involvement in patients with fungemia at a tertiary care hospital. J Vitreoretin Dis. 2025;9(3):318–322.
7.
OzturkYAğınAGencogluAY.Evaluation of axial length and refractive results in patients with dense vitreous hemorrhage who have phacovitrectomy. J Vitreoretin Dis. 2025;9(3):323–329.
8.
SharmaAHolzFGKumarN, et al. Biosimilar ranibizumab (Ranieyes) safety and efficacy in the real world: BRESER study. J Vitreoretin Dis. 2025;9(3):330–335.
9.
GibsonLNguyenARidgewayJ, et al. Postoperative methotrexate to reduce reoperation rate and improve vision in patients with complex retinal detachments, advanced diabetic retinopathy, and trauma. J Vitreoretin Dis. 2025;9(3):336–342.
10.
NawrockaZADulczewska-CicheckaKZającMGalusTATrębinskaMNawrockiJ.Switch to aflibercept after chronic treatment with bevacizumab for choroidal neovascularization with age-related macular degeneration. J Vitreoretin Dis. 2025;9(3):343–350.
11.
DayHRJrNairAAFinnAP.Visual outcomes and complications: staged vs simultaneous pars plana vitrectomy and scleral-sutured intraocular lens placement. J Vitreoretin Dis. 2025;9(3):351–356.
12.
LightJSchratzKENanegrungsunkORudnickNArmaniosMBresslerNM.Adult-onset presentations of retinopathy associated with short telomere syndromes. J Vitreoretin Dis. 2025;9(3):357–361.
13.
ShahSLopez-FontFFanJ, et al. COL2A1 mutation causing pediatric macular chorioretinal atrophy associated with Stickler syndrome. J Vitreoretin Dis. 2025;9(3):362–366.
14.
DameronCMMajaAKMehraDBatraNN.Belzutifan as the primary treatment of bilateral juxtapapillary retinal hemangioblastoma in a patient with von Hippel-Lindau disease. J Vitreoretin Dis. 2025;9(3):367–371.
15.
Bayram-SuverzaMRamírez-EstudilloA.Spontaneous resolution and asynchronous onset of stellate nonhereditary idiopathic foveomacular retinoschisis in the contralateral eye. J Vitreoretin Dis. 2025;9(3):372–376.
16.
HusainAWinebrakeJPGoldbergNRMahrousMAKovacsKD.Delayed-onset white-dot syndrome in the setting of traumatic choroidal rupture. J Vitreoretin Dis. 2025;9(3):377–381.
17.
Dias Lopes UrzedoABMichelsBDHokazonoK.Sub-inner limiting membrane hemorrhage secondary to dengue fever treated with Nd:YAG laser hyaloidotomy. J Vitreoretin Dis. 2025;9(3):382–384.
18.
PetrashCCLaneRG.Suprachoroidal injection of tattoo ink. J Vitreoretin Dis. 2025;9(3):385–387.
19.
VemulapalliDBasuSNayakSSahooNK.Bilateral sequential ocular vascular occlusions with subsequent unilateral acute retinal necrosis in a patient with HIV infection. J Vitreoretin Dis. 2025;9(3):388–391.
